Expanding the Immunotherapeutic Toolkit for Late Stage Skin Cancer

Expanding the Immunotherapeutic Toolkit for Late Stage Skin Cancer

Focus on the Rationale and Evidence?Based Role for PD?1 Targeted Immune Checkpoint Inhibition?Defining Unmet Needs in a challenging Patient Population.


Published

December 26, 2018

Created by

CMEducation Resources symposium

Related Presenters

Darrell Rigel, MS, MD

Darrell Rigel, MS, MD

Program ChairClinical Professor of DermatologyNew York Medical CenterNew York, NY